-
01:13:16 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

Trending News

Covid-19 News LIVE

The stock market news feed is automatically updated to show the latest 50 news.
The news is in real time for GOLD users while a 15 second delay is applied for FREE users.

Become a Gold member to unlock the feed filters, voice notification and see the news without delay.

Check out our Stock Market News Today and Join our Discord

Do NOT follow this link!
11/29/21 7:00 AM
Nasdaq : IMNM
covid-19low float
Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19
Immunome, Inc., a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for IMM-BCP-01, a three-antibody cocktail, for the treatment of SARS-CoV-2.
RHEA-AI
neutral
11/29/21 7:00 AM
Nasdaq : GRTS
covid-19
The Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained within Gritstone’s Self-Amplifying mRNA COVID-19 Vaccines
Omicron mutations, while impacting Spike substantially, have minimal impact (~2%) on the T Cell Epitope (TCE) sequences included within Gritstone’s COVID-19 vaccines (CORAL program) T cell immunity against conserved non-Spike epitopes may offer clinical benefit Gritstone-sponsored, CEPI-funded
RHEA-AI
neutral
11/29/21 6:31 AM
Nasdaq : NRXP
covid-19
NRx Pharmaceuticals Identifies Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in ZYESAMI® (aviptadil) Treated Patients Previously Administered Remdesivir
Analysis was conducted in the subgroup of ZYESAMI- and placebo-treated patients who were previously treated with remdesivir in the COVID-AIV trial representing approximately 70 percent of the study population Analysis was conducted in response to US Food and Drug Administration (FDA) request for
RHEA-AI
neutral
11/29/21 6:00 AM
Nasdaq : APDN
covid-19low float
Applied DNA Announces Strategy to Address Omicron SARS-CoV-2 Variant, Introduces Linea™ 2.0 COVID-19 Assay Kit
Applied DNA Sciences, Inc., a leader in Polymerase Chain Reaction- based DNA manufacturing and nucleic acid-based technologies, today announced its COVID-19 diagnostic strategy in response to the emergence of Omicron, a newly identified SARS-CoV-2 variant of concern. The Company plans to introduce its Linea™ 2.0 COVID-19 Assay, a new RT-PCR assay for the...
RHEA-AI
neutral
11/26/21 10:06 AM
Nasdaq : NRXP
covid-19
NRx Pharmaceuticals Notes New Data on BriLife® COVID-19 Vaccine Effectiveness Against Delta Variant Posted by Israel Institute for Biological Research
Analysis of Blood Samples from Patients who Responded to the BriLife ® Vaccine During Phase 2 Trial Suggests that the Same Level of Response was Seen Against the Delta Variant as Against the Original “Wild-Type” Virus Data Suggest that the BriLife Vaccine May Be Capable of Evolving to Counter Delta
RHEA-AI
negative
11/26/21 7:01 AM
Nasdaq : OCGN
clinical trialcovid-19high short
Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced that the U.S. Food and Drug Administration (FDA) has issued a clinical hold on the Company’s
RHEA-AI
neutral
11/26/21 6:45 AM
NYSE : MRK
covid-19
Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the MOVe-OUT study of molnupiravir, an investigational oral antiviral medicine for COVID-19. Based on the study design, the definitive evaluation of efficacy was considered complete at the planned interim analysis, when...
RHEA-AI
neutral
11/22/21 8:17 AM
Nasdaq : BIOC
covid-19low float
Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season
Biocept, Inc., a leading provider of molecular diagnostic assays, products, and services, now offers a single test that can detect and distinguish between SARS-CoV-2 and influenza, helping patients and caregivers determine appropriate treatment decisions. “As we navigate through a complicated flu season, expanding our COVID-19 testing services to include...
RHEA-AI
neutral
11/22/21 6:45 AM
NYSE, Nasdaq : PFE, BNTX
clinical trialcovid-19
Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
Pfizer Inc. and BioNTech SE today announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in individuals 12 through 15 years of age. This is especially important as we see rates of COVID-19 climbing in this age group in some regions, while vaccine uptake has slowed,” said Albert Bourla,...
RHEA-AI
neutral
11/22/21 6:45 AM
Nasdaq : BNTX
clinical trialcovid-19
Follow-Up Data from Phase 3 Trial Of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
Pfizer-BioNTech vaccine demonstrated 100% efficacy against COVID-19 in longer-term analysis, with no serious safety concerns identified Data will support planned submissions for full regulatory approval of the vaccine in this age group in the U.S. and worldwide NEW YORK and MAINZ, GERMANY, November
RHEA-AI
neutral
11/19/21 4:13 PM
Nasdaq : MRNA
covid-19
U.S. CDC Advisory Committee on Immunization Practices Recommends Booster Vaccination with Moderna’s COVID-19 Vaccine
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines today announced that the U.S. Centers for Disease Control and Prevention’ s Advisory Committee on Immunization Practices voted today to recommend the use of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 18 and older under the...
RHEA-AI
neutral
11/19/21 8:25 AM
NYSE, Nasdaq : PFE, BNTX
covid-19
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
Pfizer Inc. and BioNTech SE today announced that the U.S. Food and Drug Administration has expanded the emergency use authorization of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 18 years of age and older. “As we near the two-year mark in our fight against COVID-19, we have reached another critical...
RHEA-AI
neutral
11/19/21 8:07 AM
Nasdaq : MRNA
covid-19
Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, today announced that the U.S. Food and Drug Administration has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. “This emergency use authorization comes at a critical time...
RHEA-AI
neutral
11/19/21 7:30 AM
OTC : TOMDF
clinical trialcovid-19
Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients
Enrollment now paused in the randomized, double blind, placebo controlled clinical trial in severe and critical hospitalized COVID-19 patients to complete interim analysis Data from the interim analysis expected in the end of 4th Quarter of 2021 Jules Mitchel, PhD, appointed as strategic advisor to
RHEA-AI
neutral
11/18/21 9:15 AM
Nasdaq : MYMD, ORMP
covid-19
MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America
MyMD Pharmaceuticals, Inc., a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company Oravax Medical Inc., partially owned with its majority partner Oramed Pharmaceuticals Inc., has established a 50– 50 joint venture with Genomma Lab Internacional, S.A.B. de C.V., a leading pharmaceutical...
RHEA-AI
positive
11/18/21 9:00 AM
Nasdaq : IBRX
covid-19
ImmunityBio Expands Vaccine Program to Accelerate Use of “Mix-and-Match” Technologies in Developing and Manufacturing Next-Generation COVID-19 Vaccines
ImmunityBio, Inc., a clinical-stage immunotherapy company, today announced the expansion of the company’ s cancer and infectious disease vaccine programs to include self-amplifying self-adjuvating RNA, recombinant protein vaccine candidates, and potent adjuvant formulations that enhance the quality, durability and breadth of immune responses to...
RHEA-AI
positive
11/18/21 7:00 AM
NYSE, Nasdaq : AZN
covid-19
New Analyses of Two AZD7442 COVID-19 Phase III Trials in High-Risk Populations Confirm Robust Efficacy and Long-Term Prevention
New data from the AZD7442 COVID-19 PROVENT prevention and TACKLE outpatient treatment Phase III trials both showed robust efficacy from a one-time intramuscular dose of the long-acting antibody combination. In an analysis of the ongoing PROVENT trial evaluating a median six months of participant follow-up, one 300 mg IM dose of AZD7442 reduced the risk of...
RHEA-AI
neutral
11/18/21 6:45 AM
NYSE : PFE
covid-19
Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
Pfizer Inc. today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID™, subject to regulatory authorization from the U.S. Food and Drug Administration. Pfizer is seeking Emergency Use Authorization of PAXLOVID with the U.S. FDA; rolling submissions have...
RHEA-AI
very positive
11/17/21 8:14 AM
Nasdaq : MRNA
covid-19
Moderna Files for Authorization of its COVID-19 Vaccine with Health Canada to Include Children Ages 6-11 Years
Moderna Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, today announced that it has submitted for authorization with Health Canada for the evaluation of a 50 µg two-dose series of SPIKEVAX™ 1 in children ages 6 to 11 years. “We are pleased to announce that we have submitted for authorization of a 50 µg two-dose series of our...
RHEA-AI
neutral
11/17/21 8:00 AM
NYSE : WAT
covid-19
Waters’ 2021 Sustainability Report Highlights Progress on ESG Initiatives and Response to COVID-19
Waters Corporation today released its 2021 Sustainability Report, highlighting companywide achievements such as reductions in environmental impacts, supply chain enhancements and diversity and inclusion initiatives. Udit Batra, Waters President and CEO.“ Our efforts are focused on ensuring we leave the world better than we found it, becoming more...
RHEA-AI
positive